PDF(Pubmed)
Abstract：
BACKGROUND: Anti-glaucoma eye drops have been investigated due to their production of fibrotic changes on the conjunctival surface, undermining the functioning of the upper lacrimal drainage system. We aimed to assess whether these effects may impair the effectiveness of endoscopic endonasal dacryocystorhinostomy (EE-DCR).
METHODS: This is a single-center observational retrospective study on EE-DCR via a posterior approach. Resolution of epiphora and dacryocystitis were analyzed after 1 (T1) and 6-months (T2) from surgery. Surgical success was defined as anatomical (patency at irrigation, no recurring dacryocystitis) or complete (zeroing of Munk score).
RESULTS: Twenty patients (32 sides) were enrolled. Preoperatively, 93.75% (n = 30/32) presented severe (Munk 3-4) epiphora and 68.75% (n = 22/32) recurrent dacryocystitis. At T1, 50.0% (n = 16/32) were referred with residual epiphora (Munk ≥ 1) and 18.75% (n = 6/32) dacryocystitis. At T2, 31.25% (n = 10/32) still complained of epiphora (Munk ≥ 1) and 6.25% (n = 2/32) dacryocystitis. Difference of outcomes at aggregate and paired timepoints (except for T1 versus T2) resulted in statistical significance (p < 0.05). At T2, 22 (68.75%) complete, 8 (25.0%) anatomical successes and 2 (6.25%) surgical failures were observed.
CONCLUSIONS: Despite the chronic uptake of anti-glaucoma eye drops, EE-DCR guaranteed high rates of clinical relief from epiphora and remarkable decreases in the rates of recurrent dacryocystitis.
METHODS: This is a single-center observational retrospective study on EE-DCR via a posterior approach. Resolution of epiphora and dacryocystitis were analyzed after 1 (T1) and 6-months (T2) from surgery. Surgical success was defined as anatomical (patency at irrigation, no recurring dacryocystitis) or complete (zeroing of Munk score).
RESULTS: Twenty patients (32 sides) were enrolled. Preoperatively, 93.75% (n = 30/32) presented severe (Munk 3-4) epiphora and 68.75% (n = 22/32) recurrent dacryocystitis. At T1, 50.0% (n = 16/32) were referred with residual epiphora (Munk ≥ 1) and 18.75% (n = 6/32) dacryocystitis. At T2, 31.25% (n = 10/32) still complained of epiphora (Munk ≥ 1) and 6.25% (n = 2/32) dacryocystitis. Difference of outcomes at aggregate and paired timepoints (except for T1 versus T2) resulted in statistical significance (p < 0.05). At T2, 22 (68.75%) complete, 8 (25.0%) anatomical successes and 2 (6.25%) surgical failures were observed.
CONCLUSIONS: Despite the chronic uptake of anti-glaucoma eye drops, EE-DCR guaranteed high rates of clinical relief from epiphora and remarkable decreases in the rates of recurrent dacryocystitis.
摘要：
背景：已经研究了抗青光眼滴眼液，因为它们在结膜表面产生纤维化变化，破坏上泪道引流系统的功能。我们的目的是评估这些作用是否会损害鼻内镜下泪囊鼻腔吻合术（EE-DCR）的有效性。
方法：这是一项通过后路对EE-DCR进行的单中心观察性回顾性研究。手术后1（T1）和6个月（T2）分析了泪液和泪囊炎的消退。手术成功被定义为解剖学(冲洗时通畅，无复发性泪囊炎）或完全（Munk评分归零）。
结果：纳入20例患者（32侧）。术前,93.75％（n=30/32）出现严重（Munk3-4）上泪液和68.75％（n=22/32）复发性泪囊炎。在T1时，50.0％（n=16/32）被转诊为残留的泪囊炎（Munk≥1）和18.75％（n=6/32）。在T2时，仍有31.25％（n=10/32）的泪滴（Munk≥1）和6.25％（n=2/32）的泪囊炎。在总时间点和配对时间点(除了T1与T2)的结果差异导致统计学意义(p<0.05)。在T2，22（68.75%）完成，观察到8例（25.0％）解剖成功和2例（6.25％）手术失败。
结论：尽管抗青光眼滴眼液长期服用，EE-DCR保证了泪溢的高临床缓解率，并显着降低了泪囊炎的复发率。
方法：这是一项通过后路对EE-DCR进行的单中心观察性回顾性研究。手术后1（T1）和6个月（T2）分析了泪液和泪囊炎的消退。手术成功被定义为解剖学(冲洗时通畅，无复发性泪囊炎）或完全（Munk评分归零）。
结果：纳入20例患者（32侧）。术前,93.75％（n=30/32）出现严重（Munk3-4）上泪液和68.75％（n=22/32）复发性泪囊炎。在T1时，50.0％（n=16/32）被转诊为残留的泪囊炎（Munk≥1）和18.75％（n=6/32）。在T2时，仍有31.25％（n=10/32）的泪滴（Munk≥1）和6.25％（n=2/32）的泪囊炎。在总时间点和配对时间点(除了T1与T2)的结果差异导致统计学意义(p<0.05)。在T2，22（68.75%）完成，观察到8例（25.0％）解剖成功和2例（6.25％）手术失败。
结论：尽管抗青光眼滴眼液长期服用，EE-DCR保证了泪溢的高临床缓解率，并显着降低了泪囊炎的复发率。
